Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614 This issue Cite

Erratum

PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum

Peng Du, Kaifeng Luo, Guoyong Li, Jisheng Zhu, Qi Xiao, Yong Li✉, Xingjian Zhang✉

Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

✉ Corresponding authors: Xingjian Zhang, Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwai Zheng Street, Nanchang, Jiangxi 330006, China. E-mail: lfyzhangbocom. Yong Li, Department of General Surg More

Citation:
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614. https://www.medsci.org/v19p0486.htm
Other styles

File import instruction

Corrected-article in Int J Med Sci, Volume 18, 3588

Citation styles

APA
Du, P., Luo, K., Li, G., Zhu, J., Xiao, Q., Li, Y., Zhang, X. (2022). PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. International Journal of Medical Sciences, 19(3), 486-487. https://doi.org/10.7150/ijms.71614.

ACS
Du, P.; Luo, K.; Li, G.; Zhu, J.; Xiao, Q.; Li, Y.; Zhang, X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int. J. Med. Sci. 2022, 19 (3), 486-487. DOI: 10.7150/ijms.71614.

NLM
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614. https://www.medsci.org/v19p0486.htm

CSE
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. 2022. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci. 19(3):486-487.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

©2022 Ivyspring International Publisher. Terms of use